Ascletis Pharma, Inc. (1672) Stock Statistics & Valuation Metrics

Ascletis Pharma, Inc. has a market cap or net worth of HK$5.19B. The enterprise value is -HK$1.41B.

Ascletis Pharma, Inc. has 967.96M shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascletis Pharma, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Ascletis Pharma, Inc. is ―. Ascletis Pharma, Inc.’s PEG ratio is ―.

In the last 12 months, Ascletis Pharma, Inc. had revenue of HK$10.09M and earned -HK$258.47M in profits. Earnings per share was -HK$0.24.

In the last 12 months, operating cash flow was -HK$279.62M and capital expenditures -HK$4.36M, giving a free cash flow of -HK$283.98M billion.

Ascletis Pharma, Inc. pays an annual dividend of , resulting in a dividend yield of

Ascletis Pharma, Inc. upcoming earnings date is Aug 25, 2025, TBA.

Ascletis Pharma, Inc. as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Ascletis Pharma, Inc. has paid -HK$916.00K in taxes.

Ascletis Pharma, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Ascletis Pharma, Inc. has HK$2.09B in cash and marketable securities with HK$8.85M in debt, giving a net cash position of -HK$2.08B billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Ascletis Pharma, Inc. is HK$3.94, which is 11.43% higher than the current price. The consensus rating is Hold